As previously reported, Scotiabank downgraded Healthpeak to Sector Perform from Outperform with a price target of $24, down from $27. Following a deep dive into the biotech/pharma companies that are tenants in the company’s Life Science segment, the firm now expects a tougher operating environment in 2023-2024 for the Life Science segment that makes up 50% of NOI, the analyst tells investors. The firm sees a scenario where early-stage biotech startup formation is slowing at the same time that sublease space is rising across South San Francisco, San Diego and Boston, Scotiabank warns.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PEAK:
- Healthpeak downgraded to Sector Perform from Outperform at Scotiabank
- Healthpeak announces closing of holding company reorganization
- Healthpeak sees FY23 adjusted FFO $1.70-$1.76, consensus $1.79
- Healthpeak reports Q4 adjusted FFO 44c, consensus 43c
- Healthpeak Properties Reports Fourth Quarter and Year Ended 2022 Results